Patents by Inventor Richard J. Armitage

Richard J. Armitage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated Epstein-Barr virus BZLF2 proteins that bind MHC class II .beta.chains
    Patent number: 5925734
    Abstract: Isolated viral proteins, and pharmaceutical compositions made therefrom, are disclosed which are capable of binding to a .beta. chain of a Class II Major Histocompatibility Complex antigen, thereby functioning to inhibit an antigen-specific response. The viral proteins also have superantigen-like activity, and inhibit EBV infection.
    Type: Grant
    Filed: September 24, 1997
    Date of Patent: July 20, 1999
    Assignee: Immunex Corporation
    Inventors: Mark Alderson, Richard J. Armitage, Jeffrey I. Cohen, Michael R. Comeau, Theresa M. Farrah, Lindsey M. Hutt-Fletcher, Melanie K. Spriggs
  • Antibodies to CD40
    Patent number: 5801227
    Abstract: The present invention provides monoclonal antibodies and binding proteins which specifically bind to CD40 and are capable of blocking binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: September 1, 1998
    Inventors: William C. Fanslow, III, JoDee Zappone, Mark Alderson, Richard J. Armitage
  • CD30 ligand conjugates
    Patent number: 5753203
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides and oligomers find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Grant
    Filed: December 20, 1995
    Date of Patent: May 19, 1998
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • Isolated epstein-barr virus BZLF2 proteins that bind MHC class II beta chains
    Patent number: 5726286
    Abstract: Isolated viral proteins, and pharmaceutical compositions made therefrom, are disclosed which are capable of binding to a .beta. chain of a Class II Major Histocompatibility Complex antigen, thereby functioning to inhibit an antigen-specific response. The viral proteins also have superantigen-like activity, and inhibit EBV infection.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: March 10, 1998
    Assignee: Immunex Corporation
    Inventors: Mark Alderson, Richard J. Armitage, Jeffrey I. Cohen, Michael R. Comeau, Theresa M. Farrah, Lindsey M. Hutt-Fletcher, Melanie K. Spriggs
  • Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules
    Patent number: 5716623
    Abstract: Isolated viral proteins, and compositions made therefrom, are disclosed which are capable of binding to Class II Major Histocompatibility Complex antigen, thereby functioning to inhibit an antigen-specific response. The isolated viral proteins also act as superantigens.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 10, 1998
    Assignee: Immunex Corporation
    Inventors: Zhengbin Yao, Melanie K. Spriggs, Mark Alderson, Richard J. Armitage
  • Antibodies directed against CD30 ligand
    Patent number: 5677430
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Grant
    Filed: December 12, 1995
    Date of Patent: October 14, 1997
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • Method of preventing or treating disease characterized by neoplastic cells expressing CD40
    Patent number: 5674492
    Abstract: There is disclosed a method of treating a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer. CD40 binding proteins include monoclonal antibodies to CD40, and CD40 ligand. CD40 binding proteins may also be used to prevent disease characterized by neoplastic cells that express CD40, in individuals at risk for such disease.
    Type: Grant
    Filed: December 21, 1994
    Date of Patent: October 7, 1997
    Assignees: Immunex Corporation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Richard J. Armitage, William C. Fanslow, III, Dan L. Longo, William J. Murphy
  • CD27 ligand
    Patent number: 5573924
    Abstract: CD27 ligand (CD27L) polypeptide and DNA sequences, vectors and transformed host cells useful in providing CD27L polypeptides. The CD27L polypeptide binds to the CD27 receptor.
    Type: Grant
    Filed: August 13, 1993
    Date of Patent: November 12, 1996
    Assignee: Immunex Corporation
    Inventors: M. Patricia Beckmann, Raymond G. Goodwin, Judith G. Giri, Richard J. Armitage
  • Detection of mutations in a CD40 ligand gene
    Patent number: 5565321
    Abstract: There is disclosed a method of detecting a mutation in a CD40 ligand gene, comprising isolating nucleic acid from an individual, selectively amplifying nucleic acid derived from the CD40 ligand gene, and analyzing the amplified nucleic acid to determine if there is a mutation (or mutations) in the CD40 ligand gene. The ability of a CD40 ligand protein expressed from the gene may be determined. Methods of treating a syndrome that results in elevated levels of serum IgM and diminished levels of all other isotypes of immunoglobulins are also disclosed. Also disclosed are non-human animals that lack functional CD40 ligand as a result of gene targeting technology.
    Type: Grant
    Filed: January 21, 1994
    Date of Patent: October 15, 1996
    Assignee: Immunex Corporation
    Inventors: Melanie K. Spriggs, Richard J. Armitage, William C. Fanslow, III
  • CD30 ligand
    Patent number: 5480981
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Grant
    Filed: April 12, 1994
    Date of Patent: January 2, 1996
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • Interleukin-4 binding protein-.gamma.
    Patent number: 5223605
    Abstract: Isolated and purified Interleukin-4 Binding Protein-.gamma. (IL-4bp.gamma.) and methods for obtaining isolated and purified IL-4bp.gamma..
    Type: Grant
    Filed: October 16, 1990
    Date of Patent: June 29, 1993
    Assignee: Immunex Corporation
    Inventors: William C. Fanslow, Richard J. Armitage